New combo therapy targets rare abdominal cancer
NCT ID NCT03875144
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding a special chemotherapy spray (PIPAC) directly into the abdomen to standard IV chemo can help people with a rare cancer of the belly lining (peritoneal mesothelioma) live longer. About 66 adults who have not had prior treatment will be randomly assigned to receive either standard chemo alone or standard chemo plus PIPAC. The trial is currently suspended.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT PERITONEAL MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institut réginal du Cancer de Montpellier
Montpellier, 34298, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Lab-Grown tumor models predict the best therapy for each patient?
- Abdominal chemotherapy after surgery may improve mesothelioma outcomes
- Triple chemo cocktail aims to clear deadly bowel blockages in advanced stomach cancer
- Chemotherapy sprayed directly into the abdomen: a new attack on stubborn cancers
- New drug combo aims to tackle Chemotherapy-Resistant colorectal cancer in the abdomen
- Light-Activated therapy shows promise for tumor control without surgery